Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPO102 in advanced pancreatic and gastric cancers
NCT05043987Phase 1Withdrawn
- Sponsor
- Conjupro Biotherapeutics, Inc.
- Start
- Nov 2022
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 1, open-label trial of SYSA1801 in pancreatic cancer (PC) and gastric cancer (GC) (3 arms), sponsored by Conjupro Biotherapeutics, Inc. Primary endpoint: Dose-Limiting Toxicities. Planned start Nov 2022; status: withdrawn.
02
Drugs
SYSA1801
03
Conditions
pancreatic cancer (PC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT05043987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05043987.